Serum Institute inks deal to produce US-based biotech firm Novavax’s Covid vaccine

MUMBAI: US-based biotech firm Novavax has awarded licences to the Serum Institute of India (SII) for the manufacture and sale of its Covid-19 vaccine. The two companies entered into a supply and licence agreement under which Novavax granted exclusive and non-exclusive licences to SII for development, co-formulation, filling and finishing, registration and commercialisation of its NVX-CoV2373 vaccine product for the SARS-CoV-2 virus.

SII will buy the vaccine components from Novavax and the two companies will equally split the revenue from the sale of the product, net of agreed costs, Novavax said in a US regulatory filing on Wednesday.

Adar Poonawala, CEO of SII, had told ET in an interview published on July 22 that the company was in talks with Novavax for a supply agreement.

The licences granted to SII provide exclusive rights in India during the term of the supply and license agreement. SII will have non-exclusive rights during the pandemic period (as declared by the World Health Organization) in all countries other than those designated by the World Bank as upper-middle or high-income countries, Novavax said.

SII has now signed two agreements for the supply of Covid-19 vaccines, the first being AstraZeneca-Oxford’s candidate, for which the company has agreed to produce up to 1 billion doses for low and middle-income countries. The Oxford University vaccine candidate has received permission to start phase 2 and 3 trials in India.


Leave a Reply